Ocean Biomedical, Inc. (OCEA)

NASDAQ: OCEA · IEX Real-Time Price · USD
1.760
+0.060 (3.53%)
May 17, 2024, 4:00 PM EDT - Market closed
3.53%
Market Cap 60.64M
Revenue (ttm) n/a
Net Income (ttm) -98.59M
Shares Out 34.65M
EPS (ttm) -3.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 134,687
Open 1.730
Previous Close 1.700
Day's Range 1.651 - 1.780
52-Week Range 0.520 - 12.080
Beta 1.64
Analysts Strong Buy
Price Target 18.50 (+951.14%)
Earnings Date May 28, 2024

About OCEA

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 9
Stock Exchange NASDAQ
Ticker Symbol OCEA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for OCEA stock is "Strong Buy." The 12-month stock price forecast is $18.5, which is an increase of 951.14% from the latest price.

Price Target
$18.5
(951.14% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease

Providence, RI, May 16, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) announced today that Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been granted a new patent for his malaria...

2 days ago - GlobeNewsWire

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

PROVIDENCE, Rhode Island, April 24, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on April 18, 2024, it received a notice from The Nasdaq Stock Market LLC (“Nasd...

24 days ago - GlobeNewsWire

Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL

Providence, RI, March 28, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ:  OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scient...

7 weeks ago - GlobeNewsWire

Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting

Providence, RI, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ:  OCEA), a biopharma company which endeavors to accelerate the development of compelling discoveries from top research...

2 months ago - GlobeNewsWire

Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody

Results published in the Journal Immunity share discovery of a new mechanism by which Chi3L1 regulates breast cancer development and progression

5 months ago - GlobeNewsWire

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

PROVIDENCE, Rhode Island, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on November 22, 2023, it received a notice from The Nasdaq Stock Market LLC (“Na...

6 months ago - GlobeNewsWire

Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics

Providence, Rhode Island, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company working to accelerate the development of compelling discoveries from top ...

6 months ago - GlobeNewsWire

Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus Infection

Providence, RI, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientist...

7 months ago - GlobeNewsWire

Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic Hepatitis B Virus Infection

PHILADELPHIA , Oct. 26, 2023 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and its Joint Venture partner, Ocean Biomed...

7 months ago - PRNewsWire

Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan Kurtis

Providence, RI, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that its Chief Scientist, Jonathan Kurtis MD, PhD has received the prestigious Falk Medical Res...

7 months ago - GlobeNewsWire

Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics

Providence, Rhode Island, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research...

7 months ago - GlobeNewsWire

Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients Worldwide

Providence, Rhode Island, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research...

7 months ago - GlobeNewsWire

Virion Therapeutics and Ocean Biomedical form joint venture supporting multi-national, first-in-humans clinical chronic hepatitis B study: now enrolling, with goal of a functional cure for a disease affecting 300+ million patients worldwide

PHILADELPHIA , Oct. 12, 2023 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and Ocean Biomedical, Inc. (NASDAQ: OCEA), ...

7 months ago - PRNewsWire

Updated: Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with Polar Multi-Strategy Master Fund

Providence, RI, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announces that the company and Polar Multi-Strategy Master Fund (Polar) entered into a Side Letter related to th...

8 months ago - GlobeNewsWire

Ocean Biomedical Announces Loan Commitment from Largest Stockholder; Up to $10 Million

Providence, RI, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that it has entered into a non-binding term sheet with its largest stockholder, Poseidon Bio, LL...

8 months ago - GlobeNewsWire

Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with a Key Financing Partner

Providence, RI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that the company and Polar Multi-Strategy Master Fund (Polar), a significant long-time financing...

8 months ago - GlobeNewsWire

Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca's Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers

Company t o H ost Cancer R&D Update on October 1 9 , 2023 to S hare L atest D etails of M ultipronged C ancer P rogram Based on Pioneering Anti-C HI 3L1 Discoveries

8 months ago - GlobeNewsWire

Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S.

Ocean ' s small molecule candidate significantly controls fibrosis progression in i diopathic p ulmonary f ibrosis (IPF) and Hermansky-Pudlak Syndrome (HPS) in multiple testing models. Patent granted ...

9 months ago - GlobeNewsWire

Ocean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple Cancers

Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr.   Jack A. Elias, MD and Dr. Jonathan Kurtis, MD , PhD on September 14, 2023

10 months ago - GlobeNewsWire

Ocean Biomedical (NASDAQ: OCEA) Share Price Target Now Averaging $18.21, Based on Research and Development Progress in Three Promising Programs Generating Novel Treatment Candidates for Cancer, Malaria, and Fibrosis.

Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr.   Jack A. Elias, MD and Dr. Jonathan Kurtis, MD , PhD on September 14, 2023

10 months ago - GlobeNewsWire

Ocean Biomedical, Inc. (NASDAQ: OCEA) Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day

Ocean Biomedical's Oncology Platform currently consists of 27 Patents Issued or Pending. Ocean Biomedical's first-in-class anti-CHi3L1 therapeutic immunotherapy program has shown compounding efficacy ...

10 months ago - GlobeNewsWire

Ocean Biomedical's (NASDAQ: OCEA) mRNA-based Vaccine Candidate Generates Over 90% Killing of Malaria Parasites in Non-human Primates, Demonstrating Broad Potential for Ocean's Program to Address Global and Emerging U.S. Malaria Challenges

Multiple Patents have been received in the U.S. and Internationally for Novel Vaccine Candidate and “Whole New Class” of Malaria Therapeutics.

11 months ago - GlobeNewsWire

Ocean Biomedical, Inc. Joins the Russell 2000® Index

Ocean Biomedical ' s Inclusion in the Russell 2000 ® Index and Russell 3000 ® Index Builds Momentum for Cutting Edge Therapeutic Programs Targeting Multiple Cancers, Fibrotic Diseases, and Malaria

11 months ago - GlobeNewsWire

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces U.S. Patent Issued for Bispecific Cancer Immunotherapy Treatment With Demonstrated Killing of Tumor Cells in Lung Cancer, Brain Cancer (Glioblastoma), and Metastatic Melanoma.

Patent broadens protection around Ocean Biomedical's first-in-class anti-CHi3L1 antibody to include new bispecific approaches targeting immune checkpoints , with potential application in multiple prim...

11 months ago - GlobeNewsWire